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Abstract
The human gut microbiota makes fundamental contributions to host metabolism and immune 
system. Therefore, perturbations in its composition, a process known as dysbiosis, have an 
important role in the development of several chronicle diseases, mainly intestinal inflamma-
tory disorders. Culture-independent molecular methods are allowing scientific community 
to uncover substantive findings, thus giving a more detailed description of the human intesti-
nal microbiota. This chapter presents a review on current metagenomic approaches, based on 
next-generation sequencing technologies, for investigating bacterial taxonomic classification 
and predictive function associated with the human gut in health and disease. In this context, 
we describe recent studies that have been trying to elucidate important alterations in micro-
biome composition across individuals according to delivery mode, aging, diet and medica-
tion that might be linked to susceptibility to immune-mediated diseases. A description of the 
main bacterial taxa and genes acting in dysbiosis during inflammation, focusing on chronic 
inflammatory bowel diseases and colorectal cancer, is also explored in this chapter.
Keywords: gut microbiota, metagenomics, dysbiosis, inflammatory bowel diseases, 
colorectal cancer
1. Introduction
Microbiota is considered as an essential organ of humans and other animals, which carry out 
many functions that host cells cannot. A major portion of these mutualistic microbes is found 
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in the human gut, where they occupy niches that make contributions to nutrient processing, 
pathogen colonization resistance and mucosal immune system development [1]. The intestinal 
microbiome is formed by hundreds of different bacterial species colonizing mucosal surfaces. 
Its compositional structure differs across human populations according to geographic regions 
in the world method of delivery at childbirth, breast or bottle feeding, age, diet and medications 
[2]. Actually, the role of one individual microbiota is composed by the repertoire of expressed 
genes, known as metagenome. Impressively, it is estimated that humans possess 10 million extra 
genes from intestinal bacteria [3]. Significant perturbation of the gut microbiota can lead to a 
dysbiosis state, which compromise important functions in host immunity and raise susceptibil-
ity to immune-mediated diseases [4]. Therefore, there has been great interest in identifying the 
metagenomic content of the gut microbiota which can be used to treat or prevent diseases. In this 
context, extensive endeavor are being carried out to elucidate the gut ecosystem and molecular 
mechanisms underlying the pathogenesis of several intestinal disorders [5]. Culture-independent 
methods, in particular next-generation sequencing technologies, have prompted a huge break-
through in our knowledge regarding the microbial communities colonizing the human body and 
their functional beneficence to host health [6].
2. Metagenomic sequencing approaches for investigating intestinal 
microbiomes
2.1. Bacterial identification  by 16S rRNA gene sequencing
New generation sequencing technologies are capable of processing high amount of DNA in a 
relative short time using 16S ribosomal (16S rRNA) genetic information. Several high through-
put platforms such as 454 Roche GS FLX, Applied Biosystems SOLiD System, Illumina HiSeq 
and MiSeq System and Ion Torrent Personal Genome Machine (PGM) have been used for 
this kind of metagenomic approach [7, 8]. The molecular-based taxonomic investigation for 
bacteria employs direct sequencing of PCR-amplified small sequences of 16S rRNA gene 
from extracted DNA, generally using universal primers annealing conserved nucleotides 
to amplify one or more fragments of variable regions. As a few numbers of base pairs can 
change in a very short period of evolutionary time, amplicons around 300 bp are frequently 
enough for taxonomic assignment [9]. The sequences at a pre-defined level of identity stand 
for grouped clusters of similar sequencing reads, known as Operational Taxonomic Unit 
(OTU), which corresponds to a group of very similar 16S sequences. Reference databases 
(GreenGenes, myRDP, NCBI) are used to classify OTUs providing identification of taxonomy, 
relative frequencies and diversity of community composition in samples obtained from the 
certain ecosystem [10, 11]. This approach allows identification of new species and investi-
gation of low-abundance bacteria and even uncultivated gut microbial communities from a 
single analysis. In addition, these technologies are faster and more accurate compared to clas-
sical identification methods (cloning and culture) [12]. However, this approach has some limi-
tations regarding information about the microbiome function, mainly because several species 
of bacteria have not been characterized yet and secondly due to a great variability found 
among individuals, it is expected that the microbiota function present high redundancy, in 
which different species may occupy the same niche in the gut [13].
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2.2. Shotgun sequencing for predictive functional analyses
The whole metagenome sequencing can be performed using a shotgun approach. In such 
genomic survey strategy, multiple continuous overlapping sequences (contigs), which are 
assembled from fragmented sequences and obtained from total purified genomic DNA, are 
used for identifying genes through alignment with bacterial reference genomes and databases 
(KEGG, SEED and NCBI) [6]. Shotgun approach is quite versatile, in which the samples can 
be submitted to various methods, including nebulization, endonucleases, or sonication for 
random fragmentation of DNA, sequencing a subsequent contig assembly and annotation. 
Furthermore, advanced computational methods applying different algorithms are frequently 
being developed for more accurate assembly and annotation of genes, thus allowing func-
tional characterization in complex environments like the human gut [14, 15]. This method 
also provides identification of variants and polymorphisms and gives a more comprehensive 
understanding on the functional information of microorganism communities, for example, 
by reconstructing metabolic pathways in silico [12]. A major limitation of this strategy is that 
metagenomic sequencing of multiple individuals is extremely expensive in comparison with 
16S rRNA sequencing and generation of a large amount of data demands intense computa-
tional analysis, most of time to be performed by bioinformatics specialists [16].
2.3. Metagenomic consortium
Massive increase in the amount of data from human gut microbiota and identification of 
genes or families of genes submitted in the databases has prompted the creation of consortia 
such as the Human Microbiome Project in healthy individuals, which led to establishment 
of a reference microbial genome database according to results of 16S profiling of 242 healthy 
adults from the United States [17]. The European milestone Metagenomics of the Human 
Intestinal Tract (MetaHIT) intended to identify potential links between the association of gut 
microbiome with obesity and inflammatory bowel disease (IBD) from 540 Gb of DNA from 
stool samples of 124 healthy or sick individuals [18]. Moreover, about 1000 bacterial species 
were found and each individual in this study is estimated to contain at least 160 species, and 
in addition, 18 species of bacteria were common to 124 individuals [19]. Nevertheless, com-
plementary approaches to metagenomic studies as well as integrative analysis are required to 
understand the complex and intrinsic interactions with gut microbiota and hosts, like meta-
transcriptomics, metaproteomics for studying the functional aspects of the microbiota and 
metabolomics [20, 21].
3. The gut microbiome in health
3.1. Nutritional and metabolic functions
Gut microbiota is essential for the host digestion and nutrition, as they can produce unique 
nutrients from indigestible substrates [22]. For instance, many polysaccharides, which are found 
in vegetables from our diet, such as cellulose, xylans, resistant starch and inulin, are digested by 
certain species that colonize the intestines. Metagenomic studies revealed that the capacity to 
digest xyloglucans found in onion and lettuce is a specific trait of Bacteroides sp. [23]. Through 
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a mutualistic relationship, the digestion of non-digestible compounds by microbiota may yield 
energy for microbial growth and end products such as short-chain fatty acids (SCFAs). SCFAs, 
mainly acetate, propionate and butyrate, are an important energy source for the colonic epithe-
lium and as a key factor for regulating pro-inflammatory immune responses in the gut. Acetate 
and propionate are important for the liver and peripheral tissues as well, because they act as 
substrates for metabolic functions such as gluconeogenesis and lipogenesis [5]. The capacity of 
gut microbiomes metabolic activity, when regarding SCFAs production, may depend on how 
much complex carbohydrates are ingested through our diet and on the composition of the gut 
microbiota as well [24].
A study using a model of gnotobiotic mice demonstrated that fermentation of dietary fruc-
tans increases when animals colonized with Bacteroides thetaiotaomicron are co-colonized with 
Methanobrevibacter smithii. The first species produces more acetate and formate, whereas the 
second uses formate for methanogenesis, illustrating the importance of interaction between 
the microbiota organisms to promote nutrient fermentation and absorption and consequently 
metabolic functions [25, 26].
The ingestion of prebiotics such as inulin can promote expansion of Faecalibacterium 
­prausnitzii and Bifidobacterium sp. in humans. Both species are important for metabolic func-
tions and immune response regulation in the intestinal mucosa as they produce butyrate 
and folate, respectively. Folate can be synthesized by the large bowel microbiota and is 
essential for the synthesis of precursors of nucleic acids, contribute to epigenetic effects, 
and amino acid metabolism. For example, B.­bifidum and B. longum produce folate in high 
concentrations [27, 28].
Vitamin B12 is synthesized by different bacteria, for example, Propionibacterium freudenreichii 
and Lactobacillus reuteri [29]. Vitamin B12 and its corrinoid precursors play an important role in 
the gut microbiota as 80% of human intestinal microbes express transporters to capture corri-
noids and use vitamin B12 as a cofactor for metabolic pathways. For example, B. thetaiotaomicron 
encodes three vitamin B12 acquisition systems. Folate and vitamin B12 also serve as regulators 
of gene expression in human gut bacteria and might control genomic interactions between the 
microbiota and host [30].
3.2. Immune system regulation and resistance against opportunistic pathogens 
colonization
The mucosal immune system is responsible for maintaining gut homeostasis as it must remain 
vigilant against pathogen infections while limiting over inflammatory responses against the 
majority of commensal organisms that comprise the microbiota. Symbiotic bacteria play an 
important role in preventing inflammatory diseases, however in dysbiosis, opportunistic 
pathogens may stimulate a local immune response resulting a tissue damage. Therefore, the 
microbiota has the potential to exert both pro-inflammatory and anti-inflammatory responses, 
meaning that the balance in the composition of gut microbiome may be intrinsically involved 
in the proper function of the immune system [31, 32]. Many bacterial species from the gut 
microbiota such as Lactobacillus sp. and Bifidobacterium sp. have the ability to activate molecular 
Metagenomics for Gut Microbes58
mechanism on several cell types constituting the epithelial barrier function, such as special-
ized epithelial cells like goblet cells and paneth cells [33, 34]. Goblet cells are the main cells 
involved in mucus production, which is considered the first line of host defense against patho-
gens. Current studies reveal that several commensal microbes can stimulate Muc2 expression, 
a major component of the intestinal mucus [35].
Enterocytes, such as paneth cells, which reside at the base of the intestinal crypts, are spe-
cialized in producing antimicrobial peptides preventing overstimulation of the immune 
system by keeping commensal bacteria 50 μm apart from the small intestinal epithelial sur-
face [35]. Studies suggest that expression of these antimicrobial peptides, including RegIIIγ 
and defensins, is driven by the microbiota. Certain components of the microbiota, includ-
ing B.  thetaiotaomicron, confer resistance to Candida albicans by promoting the expression of 
H1F-1α, a transcriptional regulator that induces the expression of the antimicrobial peptide 
LL-37, with anti-Candida activity [36].
Microbiota induction of the adaptive responses of the immune system, including B cells 
and T cells, plays a central role in the defense against intestinal pathogens and regulation 
of inflammation in the gut. Certain intestinal bacterial species play a major role in the dif-
ferentiation of T cells into different subsets, including T helper cells Th1s, Th2s, Th17s and 
T regulatory cells (Tregs) [35]. The development and functionality of Tregs in the gut depend 
on the presence of specific commensal microbes. Administration of a pool containing bacte-
rial strains from the Clostridia clusters IV, XIVa and XVIII has been shown to restore the 
population of Tregs to those observed in conventional mice. One mechanism by which 
Clostridia species, including F.­prausnitzii, may enhance Treg differentiation is through pro-
duction of SCFA [37]. Similarly, vitamin A metabolite retinoic acid, whose production has 
been shown to be partly controlled by the microbiota, also supports anti-inflammatory func-
tion [38].
Production of IgA by B cells is a key factor for the host to control infections on muco-
sal surfaces, including the gastrointestinal tract. Several studies have demonstrated that 
the intestinal microbiota influences B-cell development and antibody production. The gut 
microbiota affects IgA class-switch recombination in either T-cell–independent or depen-
dent pathways. T-cell–independent produces IgA with low affinity but directed towards 
the microbiota. Bacteria that colonize the epithelial surface of the intestinal mucosa, such 
as Mucispirillum, Clostridium scindens and Akkermansia muciniphila which are segmented 
filamentous bacteria, can activate t-cell-dependent pathway and regulation of mucosal IgA 
responses [39, 40].
The microbiota can also confer resistance to pathogens by directly inhibiting them, without 
the involvement of the gut immune system. Certain commensal strains can produce and 
secrete small molecules with bacteriostatic or bactericidal activity, such as bacteriocins or 
microcins produced by Gram-positive and Gram-negative species, respectively. SCFA can 
also influence the expression of virulence factors. For example, butyrate and propionate can 
downregulate the expression of pathogenicity island 1 (SP1) genes in Salmonella typhimurium, 
which is crucial for this bacterium to invade intestinal epithelial cells. A major mechanism by 
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which the microbiota inhibits intestinal colonization by bacterial pathogens is through nutri-
ent competition [35].
3.3. Microbiome composition in human ontogeny
The gut microbiome assumes different characteristics regarding diversity, structure and func-
tional gene repertoires over human lifetime (Figure 1). From the compositional perspective, 
microbiota becomes more and more complex with time, along with periods of ecological sta-
bility and fluctuation due to new environmental expositions, until it reaches a dynamic equi-
librium in adulthood [13].
3.3.1. Birth
It is commonly accepted by scientific community that our first exposition to microbes may occur 
at birth delivery. However, recent metagenomics studies reveal that non-harmful bacteria may 
colonize the placenta, amniotic fluid and other fetal components from healthy term pregnan-
cies [41]. The bacterial taxa identified in the fetal environment present low abundance but are 
diverse, including many species associated with the oral and intestinal microbiomes, such as 
Fusobacterium spp. and Bacteroides spp. Moreover, similar bacterial communities can be found 
in meconium, suggesting that the colonization of the gut may start with intrauterine resident 
bacteria [42]. Nevertheless, the elucidation of the probable mechanism in which those bacteria 
translocate to the gut of the fetus is required to sustain the hypothesis of prenatal colonization. 
Regarding the gut microbiome just after birth, it has significantly lower diversity and higher vari-
ability among individuals compared to the microbiome in adulthood [24]. The dominant bac-
teria at phylum level in the neonatal gut include Firmicutes, Proteobacteria and Actinobacteria 
with lower levels of Bacteroidetes, a dominant phylum in the adult gut microbiome [43].
Figure 1. Intestinal microbiota in birth, childhood and adulthood. Birth delivery starts the colonization of the gut, 
thought the caesarian mode can alter the microbiome composition in newborns. In childhood, gut microbiota shows 
increased diversity due to introduction of solid foods. In adulthood, the gut microbiota achieves stability but several 
lifestyle factors may influence the microbiome composition, such as diet, physical activities, alcohol, smoking, drugs 
and hygiene.
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3.3.1.1. Mode of delivery
The modes of delivery significantly influence the neonatal microbiome [44]. In vaginally 
delivered infants, the gut is primarily colonized by bifidobacteria as well as lactobacilli and 
enterobacteria. When compared to children delivered in natural terms, the microbiomes of 
caesarian-delivered individuals show lower diversity and lower abundance of these bacterial 
taxa [45]. Moreover, infants delivered by cesarean section have more Escherichia coli as well 
as Clostridium­difficile [46]. A recent study has been trying to evaluate whether cesarean-deliv-
ered infants exposure to maternal vaginal fluids are able to colonize them with the natural 
microbiota that is supposed to be acquired during passage through the birth canal. However, 
these findings revealed that such inoculation provides minimal effect on the bacterial com-
munity of the infants, which presented fewer species and lower levels of Lactobacillus spp. and 
Bacteroides spp. comparing with samples originally obtained from vaginally delivered infants 
[47]. It is important to reiterate that despite of discrepancies between studies in the literature, 
most of them show that mode of delivery may select certain bacterial groups over other types.
3.3.2. Childhood
Previously, based on classical microbiological studies, it was thought that the human gut 
microbiome would achieve a stable status during the first 4 years of life. However, contem-
porary studies using metagenomic approaches have shown a different composition in child-
hood regarding the human gut microbiota when compared to adulthood [48, 49]. In American 
children cohorts, a study demonstrated that they present higher frequencies of Firmicutes, 
Proteobacteria and Actinobacteria and less Bacteroidetes [50]. Moreover, teenager’s microbi-
omes seem to be enriched in butyrate-producing  bacteria  such as Alistipes spp., B. vulgatus 
and B. xylanisolvens and Roseburia spp., Faecalibacterium spp., Ruminococcus spp., that seems to 
play anti-inflammatory roles [51]. Also, on a nutritional function perspective, microbiomes of 
children contain more vitamin B12-producing bacterial species than adults [52].
Although many functional features of the microbiome of children remain to be profoundly 
investigated, in general, it is known that childhood microbiome represents a dynamic eco-
system, which probably has an impact on health later in life. In this context, several environ-
mental exposures are supposed to be associated with differences found among individuals. 
These factors include drugs exposure, contact with domestic animals, hygiene, geography 
and diet [52]. Metagenomic studies suggest that diet has a determinant role for driving the 
development of childhood microbiome as it needs to adapt to different conditions of nutrients 
availability [53].
3.3.2.1.­Breast­feeding­versus­bottle­feeding
In the first years of life, the human gut microbiome is richer in genes involved in digestion of 
oligosaccharides found in breast milk, while in later childhood, due to the ingestion of solid 
foods, the gut metagenome is richer in genes involved in the digestion of polysaccharides 
and vitamin biosynthesis. Therefore, different microbe exposure in modes of feeding might 
significantly influence microbiome composition and function [52, 53]. Breast-fed children 
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show an increase in Actinobacteria and a decrease in Firmicutes and Proteobacteria, whereas 
bottle-fed ones exhibit more abundance of potential pathogens such as E. coli and C.­difficile 
[42, 54]. Interestingly, breast milk contains many compounds that might affect the micro-
biome composition of the infant gut in a positive way, such as immunoglobulin, prebiotic 
oligosaccharides and diverse maternal milk microbiota species that continually colonize the 
infant gut [55]. The majority of the studies show that the composition of the gut micro-
biota in breast-fed infants is enriched in aerobic organisms compared to formula-fed ones, 
which present higher prevalence of anaerobic and facultative anaerobic organisms such as 
Bacteroides sp. Certain Bacteroides sp. strains are able to digest milk oligosaccharides, sug-
gesting a potential competitive relationship between Bifidobacterium sp. and Bacteroides sp. in 
breast-fed infants. Metagenomic findings have been important for providing new advances 
regarding translational researches such as the development of infant formulas that are more 
similar in composition and function to breast milk. In this context, Oligosaccharide-enriched 
formulas have been developed, favoring the colonization of infants gut by greater numbers 
of bifidobacteria [43].
3.3.3. Adulthood
Healthy adult humans may harbor more than 1000 species of bacteria belonging to different 
bacterial phyla with Bacteroidetes and Firmicutes being the dominant ones [56]. The microbi-
ota of adults can achieve the highest diversity regarding human ontogeny development. There 
is also considerable variation in the intestinal environment, compared to other sites of the gut, 
and among healthy individuals. The proportion of each phylum apparently varies according 
to geographical distribution [2, 57]. For instance, some studies have shown that Firmicutes 
are more prevalent in adults in rural communities, whereas adults in industrialized societies 
seem to present higher levels of Bacteroidetes [58]. A higher Firmicutes to Bacteroidetes ratio 
has been mostly associated with metabolism function and body weight gain, although further 
investigation is required to shed light on the species-associated role in healthy individuals 
cohort across different geographical location to understand their influence in leanness/obesity 
[24]. In general, the gut microbiome in adulthood remains relatively stable through adult-
hood, except following perturbations such as pathogen infections, antibiotic drugs or drastic 
dietary shifts [13]. However, as we age, the gut microbiome is enriched in more traits associ-
ated with inflammation and metabolic dysfunction. A reduction in Bacteroides spp., Prevotella 
spp. and F.­prausnitzii and an increase in Enterobacteriaceae have been associated with an 
overall decrease in the quality of life in old age [51]. In general, the gut microbiome in the 
elder adults exhibits a higher ratio of Firmicutes to Bacteroidetes when compared to young 
adults and reduction in symbiotic microbes such as Bifidobacteria and Bacteroides [59].
4. Dysbiosis in the pathogenesis of inflammatory bowel diseases
As described above in this chapter, substantial changes in microbiota may sometimes lead 
to dysfunction resulting in a dysbiosis state. This process has an important role in diseases 
involving inflammatory responses in the gut, for example, in inflammatory bowel diseases 
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(IBDs) such as Crohn’s disease (CD) and ulcerative colitis (UC). Moreover, excessive oxidative 
long-term activity of IBD is associated with colorectal cancer (CRC) (Figure 2) [60]. IBDs have 
been considered as global health problem [61], affecting around 3.1 million people in the USA 
[62, 63]. CD and UC are chronic diseases characterized by periods of relapse and remission. 
Clinical symptoms of both diseases are similar to each other; however, UC activity is restricted 
to the colon while CD may affect any part of the gut, more frequently in the ileum and proxi-
mal colon [64].
It has been reported that patients with IBD have a reduced diversity of gut microbiota, char-
acterized by the depletion of commensal species belonging to the phylum Firmicutes and 
Bacteroidetes [65, 66]. Metagenomic studies have pointed out a decreasing in short-chain 
fatty acids (SCFAs) metabolism genes such as butyrate, which play an important role in the 
maturation of regulatory T cells, in the gut microbiota of IBD patients [67]. Moreover, it was 
observed that patients have a reduction in a number of many SCFA-producing species from 
Clostridia groups, remarkably F.­prausnitzii [68, 69]. Microbiota patterns such as the reduc-
tion in F.­ prausnitzii have been consistently associated with CD patients, during period of 
active disease or remission, from different geographical regions including Europe and South 
Asia and may thus serve as a reliable clinical marker [70, 71]. The reduction in species from 
Lactobacillus and Bifidobacterium genus has an important role in IBD pathogenesis as well, as 
these bacteria can downregulate the expression of key proinflammatory cytokines and che-
mokines in the gut [70]. In the other hand, opportunistic commensals, such as Mycobacterium 
avium sub. paratuberculosis, C.­difficile, Ruminococcus gnavus and enterobacteria, are increased 
[19]. Commensal Sulfate-reducing bacteria are considered as a key factor in the initiation and 
maintenance of IBD as these bacteria reduce disulfide bonds of the mucus barrier, thereby 
allowing exposure of the host cells to pathogenic bacteria and toxins [72]. Therefore, these 
Figure 2. Dysbiosis in pathogenesis of IBD and CRC. Increased levels of metabolites produced by opportunistic 
commensals of the gut microbiome  modulates the effects of inflammation process and cancer tumorigenesis.
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patients develop a certain predisposition for the colonization of facultative pathogens, such as 
invasive E. coli, that express several virulence factors involved in adhesion and invasion of the epi-
thelial barrier [73, 74]. Moreover, colonization by pathogenic species, such as M. paratuberculosis, 
Listeria monocytogenes or Helicobacter species, can worsen the symptoms of IBD as these bacteria 
can activate proinflammatory signaling cascades into the host [75].
Besides bacteria, gut microbiome fungi and virus may also be involved in IBD. Metagenomic stud-
ies demonstrated that inflamed guts present high frequency of certain bacteriophages [76, 77]. In 
regard of fungi, few studies in mice show some yeast species that can inhibit the over growth of 
certain opportunistic commensals and affect the gut homeostasis. However, in humans, much 
research is required to elucidate the role of fungi and virus microbiome in the gut [78].
Currently, there is much discussion about the use of fecal transplant for transference of 
microbiota from healthy individuals to IBD patients as an alternative therapeutic strategy. 
Promising outcomes have been achieved against C.­difficile infection in clinical trials, which is 
often found in the gut of IBD patients [79]. However, in UC clinical trials, the fecal transplant 
efficacy is controversial [80, 81]. Regarding CD clinical trials, children cohorts have shown 
better results with fecal microbiota transplantation than adult cohorts [82, 83].
4.1. Colorectal cancer
CRC is the most common form of gastrointestinal tract cancer, globally the third leading cause 
of cancer, and is associated with significant mortality affecting both men and women with 1.4 
million people diagnosed annually [60, 84].
Different from other kinds of cancer affecting the large bowel which are caused by point 
mutations in several genes that control cell proliferation, survival, differentiation and migra-
tion [60], CRC is mostly attributed to environmental factors and lifestyle such as high fat diet, 
alcohol, red meat, smoking, obesity, or lack of physical activity [56, 85]. There are several 
studies showing a connection between inflammatory processes and carcinogenesis, although 
the contribution of immunological mechanisms and inflammation to malignancy of CRC, it 
is not fully elucidated [86–88]. Immune cells, cytokines and other mediators of the immune 
system that are directly influenced by dysbiosis play an important role in the stages of tumori-
genesis in the colon, including onset, promotion, progression, and metastasis [86].
Several studies have been trying to identify components of the microbiota that play pivotal 
roles in inflammation process and in the progression of colorectal cancer by creating micro-
environments that favor tumorigenesis development (Table 1). Metagenomic analysis of 
microbiome provides insights of interactions and contributes to understand how the bacterial 
species can be related to CRC development, as it has been observed that bacterial popula-
tions present in fecal samples are distinct from not only tissue biopsies but also between 
inter-individual microbial communities, even in samples with the same subtypes of cancer. 
Usually fecal samples and biopsies are collected for 16S RNA gene sequencing generating 
results about diversity and abundance of the species making part of the gut microbial com-
munity [89, 90].
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Main findings Disease Sampling description Ref
Microbiomes of IBD subjects fluctuate more than those of 
healthy individuals
IBD Fecal samples from 109 
patients with IBD (CD, n = 49; 
UC, n = 60)
[100]
UC and CD have distinct microbiomes. F.­prausnitzii and 
E. coli were found decreased and increased, respectively, in 
CD. These species among others could be used as microbiome 
markers to discriminate CD and UC
IBD 2045 non-IBD and IBD fecal 
samples from four countries 
(Spain, Belgium, the UK and 
Germany)
[101]
Microbiome colonizing the mucosa is different between 
inflamed subjects with CD and UC. At phylum level, 
Bacteroidetes is more frequent in CD while Proteobacteria 
and Firmicutes were more frequently observed in UC. At 
genus level, Faecalibacterium, Bacteroides and Pseudomonas were 
significantly different between the inflamed CD and UC
IBD Analysis of the microbiota 
composition of ileum, cecum, 
mid-colon and rectum samples 
from 166 individuals
[102]
The role of the metabolites produced by the microbiota in 
dysbiosis was correlated to IBD. Dysbiosis characterized by 
changes in Firmicutes and Proteobacteria phyla.
Decreased levels of Roseburia and Faecalibacterium were found 
in CD and UC
IBD Microbiota of intestinal 
biopsies and stool samples 
from 231 IBD and healthy
[103]
Metabolites and fecal microbiome can be useful to 
discriminate between healthy subjects and patients with 
IBD. At genus level, Escherichia, Faecalibacterium, Streptococcus, 
Sutterella and Veillonella were increased, while level of 
Bacteroides, Flavobacterium and Oscillospira decreased in IBD 
group
IBD Microbiota and the metabolites 
in stool of 183 subjects 
(UC—82, CD—50 and 51 
healthy controls)
[104]
Mucosa-associated dysbiosis was identified in IBD patients. 
CD and UC may be distinguishable from the mucosa-
associated microbial community structure. CD patients have 
increased levels of Escherichia, Ruminococcus, Cetobacterium, 
Actinobacillus and Enterococcus comparing to controls and 
UC subjects, and a significant decrease in Faecalibacterium, 
Coprococcus, Prevotella and Roseburia as well
IBD 174 mucus samples from 43 
UC subjects, 26 CD subjects 
and 14 non-IBD controls
[105]
No consistent overrepresentation of potential pathogenic 
bacteria in CRC tissue
Increased abundance of Coriobacteridae, Roseburia, 
Fusobacterium and Faecalibacterium
Decreased abundance of Enterobacteriaceae (Citrobacter, 
Shigella, Cronobacter, Kluyvera, Serratia and Salmonella spp.)
CRC Resections for primary colon 
adenocarcinoma of 6 patients
[106]
The gut microbiome could be used as a biomarker for CRC
Adenoma: increased abundances of Ruminococcaceae, 
Clostridium, Pseudomonas and Porphyromonadaceae. Lower 
abundances of Bacteroides, Lachnospiraceae, Clostridiales and 
Clostridium
Carcinoma: increased abundances of Fusobacterium, 
Porphyromonas, Lachnospiraceae and Enterobacteriaceae. 
Lower abundances of Bacteroides, Lachnospiraceae and 
Clostridiales
CRC Analysis of fecal samples from 
healthy individuals, adenoma 
and carcinoma patients (30 
subject for each clinical group)
[107]
F. nucleatum is prevalent in cases of proximal colon cancer. 
Amount of F. nucleatum increases linearly along the bowel 
subsites from rectum to cecum
CRC 1102 samples provided 
from database of colorectal 
carcinoma cases
[108]
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Considering CRC microenvironment and the functionality of intestinal microbiome, it has 
a high importance as a risk factor or can be directly associated to CRC. Chronic inflamma-
tory processes driven by dysbiosis can affect all stages of tumor development by compounds 
that can damage DNA, for example, reactive oxygen species (ROS) promoting CRC devel-
opment [91]. During an inflammatory response, this microenvironment generates ROS and 
reactive nitrogen intermediates (RNIs) that lead to deleterious DNA promoting carcinogen-
esis damage or activating pivotal signaling pathways for adenoma formation and growth 
[86]. In a study investigating CRC in mouse model of tumorigenesis, it was demonstrated 
that long-term inflammation-mediated breakdown of protective intestinal barriers promotes 
the production of some inflammatory cytokines such as IL-17 and IL-23 that lead to tumor 
growth by facilitating bacterial translocation and consequently microbial products that trig-
ger tumorigenesis resulting in adenoma invasion [92]. Blooms of enterobacteria also seem to 
play a role in CRC as indicated by metagenomic studies of luminal microbiota of inflamed 
Il10−/− mice reveal that E. coli can promote cancer activity modulating tumor development 
once host inflammation has been established [87, 93].
In a study with fecal samples from 74 patients with CRC, the microbiome was enriched in 
Fusobacterium nucleatum and Peptostreptococcus stomatis. Moreover, co-occurrence of these 
taxa with the other two, Parvimonas micra and Solobacterium moorei, was found. Interestingly, 
P. micra and the Gram-negative F. nucleatum can induce inflammatory responses by bind-
ing to lipopolysaccharides from Gram-negative bacteria. Furthermore, F. nucleatum was 
shown to increase intestinal tumorigenesis through recruitment of infiltrating immune 
cells and through activation of β-catenin signaling [90]. In another study, in which the role 
of F. nucleatum in CRC was investigated by metagenomic analyses of 511 colorectal carci-
nomas from Japanese patients, it was identified a significant increase in the occurrence of 
the bacteria [89].
Main findings Disease Sampling description Ref
F. nucleatum, B. fragilis and F.­prausnitzii could be identified as 
useful prognostic biomarkers for CRC
B. fragilis and F.­prausnitzii correlated with patient’s survival 
in CRC
F. nucleatum presented higher abundance in non-survival 
group
CRC Tissues samples from 108 
patients in stages I–IV of CRC 
with different prognosis
[109]
CRC microbiome is stage-specific and appears to evolve with 
disease progression. Enrichment of organisms including 
Bacteroides fragilis, Fusobacterium nucleatum and under-
representation of Bacteroides vulgatus, Bacteroides uniformis and 
Faecalibacterium­prausnitzii
Enrichment of oral pathobionts in poor prognosis tumors 
and cancers: Parvimonas micra, Porphyromonas gingivalis and 
Prevotella spp.
CRC Tissue was sampled from 158 
CRC patients, 24 adenoma 
patients and 14 normal colon 
controls
[110]
Multiple fusobacteria members did not correlate with 
CRC. Enriched F. nucleatum, F. necrophorum, Leptotrichia 
trevisanii, B. fragilis, Parvimonas micra, Peptostreptococcus 
stomatis and Gemella morbillorum
Low levels of F. varium and Cetobacterium somerae in CRC
CRC 16S rRNA amplicon sequence 
raw datasets from 12 studies
[111]
Table 1. Recent metagenomic studies in clinical investigation of intestinal inflammatory diseases.
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An investigation in 34 patients with four CRC subtypes showed enrichment of Fusobacteria and 
Bacteroidetes, and decreased levels of Firmicutes and Proteobacteria, including Porphyromonas 
gingivalis, P. micra, P. stomatis and F. nucleatum, create a particular condition by recruiting 
T cells resembling the immunological aspects in specific colorectal tumors [94]. Prorok-Hamon 
et al. (2014) have shown, by PCR screening, that from 281 E. coli isolates from IBD patients, 
CRC patients presented increased levels of 21 colonic mucosa-associated E. coli strains, with 
pathogenic traits, including M-cell translocation, angiogenesis and genotoxicity properties [95].
Some works using metagenomics and metabolomics integrative analyses found that enriched 
levels of Fusobacteria and Proteobacteria create a specific mucosal metabolic microenviron-
ment that was associated with CRC pathogenesis through a large number of chemical and 
molecular signaling pathways [96–98]. Although fecal microbiome and metabolome may pos-
itively correlate with CRC conditions, the role of such interactions is still poorly understood 
in the pathogenesis of the disease [96].
Helicobacter pylori which well established in the development of stomach cancer since 1994 being 
classified as carcinogenic by the International Agency for Research on Cancer has also been pointed 
out as risk factor for CRC, as the infection leads to initial inflammatory response by stimulating 
IL-1β production, and consequently causing epithelium injury such as metaplasia [85]. In some 
studies, there was an indication of increased risk of colorectal adenomas by the presence of H. pylori 
due to hypergastrinemia; however, there is a controversy in other metagenomic studies that did not 
found correlation or even did not identify the presence of the pathogen in the analyzed samples [99].
5. Concluding remarks
These recent metagenomic studies reiterate that microbiome intrinsic factors from particular 
communities and lifestyle are extremely important and should be considered for future devel-
opment of novel therapies for IBD. Despite of all efforts to accurately unravel the microbiome 
role in the gut and its relationship with gut inflammation through metagenomic sequencing 
approaches, it seems that more complex mechanism might be involved in dysbiosis linked to 
chronic inflammatory diseases, such as IBD and CRC. In this context, further advances in the 
area are required to achieve a more precise definition of gut microbiome role, which could 
allow investments for the search of more effective therapies.
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